253 related articles for article (PubMed ID: 36125896)
1. H3.3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models.
Haase S; Banerjee K; Mujeeb AA; Hartlage CS; Núñez FM; Núñez FJ; Alghamri MS; Kadiyala P; Carney S; Barissi MN; Taher AW; Brumley EK; Thompson S; Dreyer JT; Alindogan CT; Garcia-Fabiani MB; Comba A; Venneti S; Ravikumar V; Koschmann C; Carcaboso ÁM; Vinci M; Rao A; Yu JS; Lowenstein PR; Castro MG
J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36125896
[TBL] [Abstract][Full Text] [Related]
2. Deposition of onco-histone H3.3-G34W leads to DNA repair deficiency and activates cGAS/STING-mediated immune responses.
Mancarella D; Ellinghaus H; Sigismondo G; Veselinov O; Kühn A; Goyal A; Hartmann M; Fellenberg J; Krijgsveld J; Plass C; Popanda O; Schmezer P; Bakr A
Int J Cancer; 2024 Jun; 154(12):2106-2120. PubMed ID: 38353495
[TBL] [Abstract][Full Text] [Related]
3. H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Pediatric High-Grade Gliomas.
Garcia-Fabiani MB; Haase S; Banerjee K; McClellan B; Zhu Z; Mujeeb A; Li Y; Yu J; Kadiyala P; Taher A; Núñez FJ; Alghamri MS; Comba A; Mendez FM; Nicola Candia AJ; Salazar B; Koschmann C; Nunez FM; Edwards M; Qin T; Sartor MA; Lowenstein PR; Castro MG
bioRxiv; 2023 Jun; ():. PubMed ID: 37398299
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours.
Haque F; Varlet P; Puntonet J; Storer L; Bountali A; Rahman R; Grill J; Carcaboso AM; Jones C; Layfield R; Grundy RG
Acta Neuropathol Commun; 2017 Jun; 5(1):45. PubMed ID: 28587626
[TBL] [Abstract][Full Text] [Related]
5. STINGing the immune system: lessons learned through a model of G34-mutant pediatric high-grade glioma.
Hall CP; Cronk JC; Rubens JA
J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36377657
[TBL] [Abstract][Full Text] [Related]
6. Aberrant DNA repair reveals a vulnerability in histone H3.3-mutant brain tumors.
Giacomini G; Piquet S; Chevallier O; Dabin J; Bai SK; Kim B; Siddaway R; Raught B; Coyaud E; Shan CM; Reid RJD; Toda T; Rothstein R; Barra V; Wilhelm T; Hamadat S; Bertin C; Crane A; Dubois F; Forne I; Imhof A; Bandopadhayay P; Beroukhim R; Naim V; Jia S; Hawkins C; Rondinelli B; Polo SE
Nucleic Acids Res; 2024 Mar; 52(5):2372-2388. PubMed ID: 38214234
[TBL] [Abstract][Full Text] [Related]
7. Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma.
Subashi E; Cordero FJ; Halvorson KG; Qi Y; Nouls JC; Becher OJ; Johnson GA
J Neurooncol; 2016 Jan; 126(2):243-51. PubMed ID: 26511492
[TBL] [Abstract][Full Text] [Related]
8. Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors.
Sangatsuda Y; Miura F; Araki H; Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Arai Y; Yoshida A; Shibata T; Yoshimoto K; Iihara K; Ito T
Sci Rep; 2020 Sep; 10(1):16162. PubMed ID: 32999376
[TBL] [Abstract][Full Text] [Related]
9. SHP2-Mediated Inhibition of DNA Repair Contributes to cGAS-STING Activation and Chemotherapeutic Sensitivity in Colon Cancer.
Wei B; Xu L; Guo W; Wang Y; Wu J; Li X; Cai X; Hu J; Wang M; Xu Q; Liu W; Gu Y
Cancer Res; 2021 Jun; 81(12):3215-3228. PubMed ID: 33820798
[TBL] [Abstract][Full Text] [Related]
10. Low-Grade Gemistocytic Morphology in H3 G34R-Mutant Gliomas and Concurrent K27M Mutation: Clinicopathologic Findings.
Morris M; Driscoll M; Henson JW; Cobbs C; Jiang L; Gocke CD; Chen L; Rodriguez FJ
J Neuropathol Exp Neurol; 2020 Oct; 79(10):1038-1043. PubMed ID: 32954438
[TBL] [Abstract][Full Text] [Related]
11. Impact of Chromatin Dynamics and DNA Repair on Genomic Stability and Treatment Resistance in Pediatric High-Grade Gliomas.
Pinto L; Baidarjad H; Entz-Werlé N; Van Dyck E
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830833
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution.
Yoshimoto K; Hatae R; Sangatsuda Y; Suzuki SO; Hata N; Akagi Y; Kuga D; Hideki M; Yamashita K; Togao O; Hiwatashi A; Iwaki T; Mizoguchi M; Iihara K
Brain Tumor Pathol; 2017 Jul; 34(3):103-112. PubMed ID: 28447171
[TBL] [Abstract][Full Text] [Related]
13. Histone H3G34R mutation causes replication stress, homologous recombination defects and genomic instability in
Yadav RK; Jablonowski CM; Fernandez AG; Lowe BR; Henry RA; Finkelstein D; Barnum KJ; Pidoux AL; Kuo YM; Huang J; O'Connell MJ; Andrews AJ; Onar-Thomas A; Allshire RC; Partridge JF
Elife; 2017 Jul; 6():. PubMed ID: 28718400
[TBL] [Abstract][Full Text] [Related]
14. Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis.
Chen CCL; Deshmukh S; Jessa S; Hadjadj D; Lisi V; Andrade AF; Faury D; Jawhar W; Dali R; Suzuki H; Pathania M; A D; Dubois F; Woodward E; Hébert S; Coutelier M; Karamchandani J; Albrecht S; Brandner S; De Jay N; Gayden T; Bajic A; Harutyunyan AS; Marchione DM; Mikael LG; Juretic N; Zeinieh M; Russo C; Maestro N; Bassenden AV; Hauser P; Virga J; Bognar L; Klekner A; Zapotocky M; Vicha A; Krskova L; Vanova K; Zamecnik J; Sumerauer D; Ekert PG; Ziegler DS; Ellezam B; Filbin MG; Blanchette M; Hansford JR; Khuong-Quang DA; Berghuis AM; Weil AG; Garcia BA; Garzia L; Mack SC; Beroukhim R; Ligon KL; Taylor MD; Bandopadhayay P; Kramm C; Pfister SM; Korshunov A; Sturm D; Jones DTW; Salomoni P; Kleinman CL; Jabado N
Cell; 2020 Dec; 183(6):1617-1633.e22. PubMed ID: 33259802
[TBL] [Abstract][Full Text] [Related]
15. Diffuse hemispheric glioma with H3-3B G34R mutation: Expanding the spectrum of histone H3 genes in diffuse hemispheric glioma, H3 G34-mutant.
Nazem A; Lavezo J; Abdullaev Z; Aldape K; Quezado M; Cimino PJ; Pratt DW; Jenkins RB; Ida CM
J Neuropathol Exp Neurol; 2023 Dec; 83(1):58-60. PubMed ID: 37878797
[No Abstract] [Full Text] [Related]
16. H3 G34-mutant high-grade glioma.
Lim KY; Won JK; Park CK; Kim SK; Choi SH; Kim T; Yun H; Park SH
Brain Tumor Pathol; 2021 Jan; 38(1):4-13. PubMed ID: 32995948
[TBL] [Abstract][Full Text] [Related]
17. Regional identity of human neural stem cells determines oncogenic responses to histone H3.3 mutants.
Bressan RB; Southgate B; Ferguson KM; Blin C; Grant V; Alfazema N; Wills JC; Marques-Torrejon MA; Morrison GM; Ashmore J; Robertson F; Williams CAC; Bradley L; von Kriegsheim A; Anderson RA; Tomlinson SR; Pollard SM
Cell Stem Cell; 2021 May; 28(5):877-893.e9. PubMed ID: 33631116
[TBL] [Abstract][Full Text] [Related]
18. Evaluating H3F3A K27M and G34R/V somatic mutations in a cohort of pediatric brain tumors of different and rare histologies.
Oliveira VF; De Sousa GR; Dos Santos AC; Saggioro FP; Machado HR; de Oliveira RS; Tone LG; Valera ET
Childs Nerv Syst; 2021 Feb; 37(2):375-382. PubMed ID: 32766947
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
[TBL] [Abstract][Full Text] [Related]
20. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas.
Fontebasso AM; Schwartzentruber J; Khuong-Quang DA; Liu XY; Sturm D; Korshunov A; Jones DT; Witt H; Kool M; Albrecht S; Fleming A; Hadjadj D; Busche S; Lepage P; Montpetit A; Staffa A; Gerges N; Zakrzewska M; Zakrzewski K; Liberski PP; Hauser P; Garami M; Klekner A; Bognar L; Zadeh G; Faury D; Pfister SM; Jabado N; Majewski J
Acta Neuropathol; 2013 May; 125(5):659-69. PubMed ID: 23417712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
